Nikolaos Kamperidis

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy, Simeng Lin, James Goodhand et al. · Gut · 2021 · 280 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Simeng Lin, Nicholas A. Kennedy, Aamir Saifuddin et al. · Nature Communications · 2022 · 81 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study

Uri Kopylov, Bram Verstockt, Luc Biedermann et al. · Inflammatory Bowel Diseases · 2018 · 68 citations

Pharmacy, Immunology, Pharmacotherapy +17

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Zhigang Liu, Kaixing Le, Xin Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 35 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Prevalence of malnutrition in medical and surgical gastrointestinal outpatients

Nikolaos Kamperidis, Luciana Tesser, Paul Wolfson et al. · Clinical Nutrition ESPEN · 2019 · 21 citations

Agriculture, Nutrition, Nutritional Sciences +12